Trust me, I can guarantee you that IF the SUCCEED trial does not meet its endpoints, the people who have been holding this stock for 15 years will be proclaiming, "We're not in this for Ridaforolimus, we're here for '534."
Which is all fine and dandy, however, without Ridaforolimus, Ariad is like a rocket WITHOUT a launching pad.